3Martin PL, Oneda S,Treacy G. Effects of an anti-TNF-alphamonoclonal antibody, administered throughout pregnancy andlactation,on the development of the macaque immune system[J],Am J Reprod Immunol, 2007, 58(2): 138-149.
4Hazes JM,Coulie PG, Geenen V,et al. Rheumatoid arthritis andpregnancy: Evolution of disease activity and pathophysiologicalconsiderations for drug use[J], Rheumatology (Oxford),2011,50(11): 1955-1968.
5Carter JD, Valeriano J , Vasey FB. Tumor necrosis factor-alphainhibition and VATER association: A causal relationship [J]. JRheumatol, 2006,33(5) ; 1014-101 7.
6Crijns HJ, Jentink J, Garne E, n al. The distribution ofcongenital anomalies within the VACTERL association amongtumor necrosis factor antagonist-exposed pregnancies is similar tothe general population [J ]. J Rheumatol, 2011,38 ( 9 ): 1871-1874.
7Carter JD, Ladhani A, Ricca LR, et al. A safety assessment oftumor necrosis factor antagonists during pregnancy: A review ofthe Food and Drug Administration database [J]. J Rheumatol,2009, 36(3): 635-641.
8Van Assche G, Dignass A, Reinisch W, et al. The secondEuropean evidence-based Consensus on the diagnosis andmanagement of Crohn,s disease: Special situations[J]. J CrohnsColitis, 2010, 4(1) ; 63-101.
9Vasiliauskas EA,Church JA, Silverman N,et al. Case report,Evidence for transplacental transfer of maternally administeredinfliximab to the newborn[J3. Clin Gastroenterol Hepatol, 2006,4(10): 1255-1258.
10Ostensen M,Eigenmann GO. Etanercept in breast milk [ J ]. JRheumatol, 2004, 31(5): 1017-1018.
